# Billions of mRNA doses, what science really says in 2026 > Introduction: a massive review, one simple question - Author: Maxime Marquette - Publisher: MadMax (https://mad-max.co) - Section: Analysis - Published: 2026-07-04 - Canonical URL: https://mad-max.co/en/article/milliards-de-doses-darnm-que-dit-vraiment-la-science-en-2026 ## Introduction: a massive review, one simple question ### Thirteen billion doses, one central question Since December **2020**, more than **thirteen billion doses** of **mRNA** vaccines have been administered worldwide. One question remains omnipresent in public debate: are these vaccines truly safe and effective at this massive scale and over this extended period? A sweeping scientific review published in **The Lancet** on **July 1, 2026** provides precise, quantified, and verifiable answers. This review, led by researcher **Anna Blakney** of the **University of British Columbia**, does not claim to definitively close every debate surrounding these vaccines, but it consolidates a considerable body of data accumulated over more than five years of worldwide use. ### Why this fact-check is necessary **Disinformation** about mRNA vaccines remains abundant online, sometimes mixing **legitimate concerns** with **unfounded claims**. This fact-check aims to clearly separate what **science** establishes, what it qualifies, and what it still cannot state with certainty. *I will be direct: I am not here to sell a medical miracle, nor to wave away legitimate concerns about rare side effects. The truth lies in precise numbers, not in enthusiasm or panic.* ## Claim 1: mRNA vaccines are effective against infection ### What the Lancet review says According to the review published in **The Lancet**, mRNA vaccines show **87%** efficacy against documented **SARS-CoV-2** infection, measured between **14 and 42 days** after full vaccination. This overall figure aggregates data from multiple studies conducted across different countries and populations. Against the **Omicron** variant, more resistant to **antibodies** than the virus's initial strains, efficacy against documented infection drops to roughly **67%**, a figure that nonetheless remains significant given this variant's known **immune-evasion capacity**. ### Verdict: TRUE, with a temporal caveat This claim is **corroborated** by the available data, but it requires an important caveat: efficacy against simple infection declines over time and against new variants, which explains the periodic booster recommendations in several Western countries. *The 87% figure is impressive, but we must resist the temptation to treat it as an absolute guarantee. Science speaks in probabilities, not certainties, and it is precisely that nuance that separates honest science communication from a marketing promise.* ## Claim 2: protection against hospitalization and death is stronger ### Notably higher figures for severe outcomes The **Lancet** review establishes an efficacy of **93%** against **hospitalization** and **94%** against **death** linked to COVID-19, figures markedly higher than those observed against simple infection. Against **Omicron** specifically, efficacy against hospitalization remains high at **72%**. This **hierarchy of protection** — stronger against severe outcomes than against simple infection — is consistent with the known **immunological mechanism** of mRNA vaccines, which train the **immune system** to respond quickly even when the initial infection is not fully blocked. ### Verdict: TRUE, and the most robust finding in the data This claim is one of the review's **most robust findings**, corroborated by multiple independent studies conducted across different national health systems, including Canadian, European, and American data, gathered through hospital admission records and mortality registries over several years, spanning multiple waves of the pandemic and several distinct viral variants. *This is the figure, protection against hospitalization and death, that deserves the most public attention. We too often focus on simple infection, when the real public health stake has always been avoiding severe forms of the disease.* ## Claim 3: myocarditis is a serious and frequent risk ### What the numbers actually show The review's data indicate **myocarditis** rates of roughly **12.6 cases per million** doses for the **Pfizer** vaccine and **35.6 cases per million** for the **Moderna** vaccine, a rare but real side effect, more common in young men after the second dose. However, the review notes that **COVID-19** infection itself causes myocarditis rates **20 to 42 times higher** than vaccination does, an essential point of **comparison** often missing from **alarmist rhetoric** on this specific subject. ### Verdict: PARTLY TRUE, essential context needed The risk of myocarditis is **real** and should not be minimized, but stating it without comparing it to the risk from natural infection produces a distorted and alarmist picture of the true benefit-risk balance of vaccination. *I refuse both to minimize vaccine-related myocarditis, which is a documented and real side effect, and to present it out of context as though the alternative — catching the virus unprotected — were safer. The numbers clearly say otherwise.* ## Claim 4: mRNA vaccines open the door to cancer treatments ### A promising avenue, but still experimental Researchers cited in the review discuss potential future applications of **mRNA** technology beyond COVID-19, notably in treating **cancer**, **influenza**, **respiratory syncytial virus**, and certain **autoimmune diseases**. These avenues rely on mRNA technology's ability to train the immune system against specific targets. These applications remain, however, at **varying stages of development**, ranging from **preliminary clinical trials** to research still largely **experimental** in the laboratory, far from immediate clinical availability for patients who might otherwise pin unrealistic hopes on headlines about breakthrough cures. ### Verdict: PROMISING BUT PREMATURE Presenting these applications as **imminent treatments** would be misleading. The review itself remains cautious, speaking of **potential** rather than established clinical results for these uses beyond COVID-19. *I resist here the temptation of scientific sensationalism. Yes, mRNA technology opens fascinating doors for the future of medicine, but turning research potential into a promise of cure would be dishonest toward patients hoping for concrete solutions today.* ## Claim 5: global access to this technology remains unequal ### A call from researchers to close the gaps The review's authors explicitly call for concentrating future efforts on **expanding access** to mRNA technology, highlighting persistent disparities between high-income and low- or middle-income countries in the distribution of these vaccines since **2020**. This **unequal access** has direct consequences for **global collective protection** against future pandemics, a **public health issue** that extends far beyond the question of the vaccine's individual efficacy alone, since uncontrolled outbreaks anywhere in the world eventually threaten populations everywhere. ### Verdict: TRUE, a documented global health equity issue This claim is **corroborated** by extensive prior data on the unequal global distribution of vaccines during the pandemic, a problem acknowledged by the entire international scientific community and repeatedly flagged by global health bodies as an unresolved structural weakness. *This equitable-access issue strikes me as under-discussed compared to the endless debates over side effects. A vaccine technology that works but fails to reach the world's most vulnerable populations remains a collective missed opportunity.* ## What this review does not say and cannot claim ### Methodological limits worth knowing This review, however extensive, aggregates data from multiple studies with sometimes differing methodologies, which introduces a margin of statistical uncertainty inherent to this type of combined analysis. Nor does it constitute a single new-generation clinical study, but rather a synthesis of already published data collected across different countries, age groups, and time periods since the start of the pandemic. Nor does it allow for stating with **absolute certainty** the nonexistence of any **rare side effect** not yet identified, as **medical science** continually progresses in detecting **weak statistical signals** across very large vaccinated populations. ### Scientific honesty above all Acknowledging these **limits** does not diminish the value of the review: it is simply an integral part of **rigorous scientific practice**, which advances through **accumulation of evidence** rather than through definitive, closed statements presented as final truths. *I prefer a science that admits its limits over communication that claims to know everything. It is precisely this methodological humility that makes this Lancet review credible in my eyes rather than suspicious.* ## Claim 6: vaccine boosters are still necessary in 2026 ### How recommendations have evolved since 2020 The question of **vaccine boosters** continues to evolve with the emergence of new **variants**. Public health authorities in several Western countries, including **Canada** and the **United States**, still recommend targeted boosters for the highest-risk populations, notably the elderly and immunocompromised individuals, rather than a repeated universal campaign for the entire population. This **targeted approach** reflects a logical evolution of **vaccine strategy**, based on the ongoing analysis of the balance between **individual benefit** and **residual risk**, rather than a uniform approach frozen since the start of the pandemic, when far less was known about which groups actually needed repeated doses. ### Verdict: TRUE, with a now-targeted approach It is accurate that booster recommendations have shifted toward a more **targeted** and less systematic approach than at the start of the vaccination campaign, reflecting a better scientific understanding of actual risk by age group and health condition. *This shift toward targeted rather than universal boosters strikes me as exactly the kind of rational scientific adjustment we should applaud, rather than viewing it as an admission of failure of the initial vaccine strategy.* ## Conclusion: what this fact-check clearly establishes ### An overall positive but nuanced record After verifying the main claims circulating around this **Lancet** review, the overall record is positive for mRNA vaccines: **high efficacy** against severe forms of disease, **rare** but real and documented **side effects**, and a **promising future potential** that remains largely experimental beyond **COVID-19**, spanning cancer, influenza, and autoimmune research still years away from clinical maturity. ### Ongoing scientific vigilance, not absolute certainty No **vaccine**, no **medical technology**, is free of **risks** or **limits**. This **fact-check** confirms that the data available in **2026** support a **favorable record** for these vaccines, while calling for continued **scientific vigilance** rather than **blind trust** or **categorical rejection**. The evidence should be revisited regularly as new variants emerge and as longer-term follow-up data continues to accumulate across vaccinated populations worldwide. *I will say it plainly: science is never a religion, it is a method that corrects itself over time as new evidence emerges. This review in **The Lancet** does not close the debate forever, it establishes a solid state of knowledge as of **July 3, 2026**, and that is already enormous in a world saturated with medical disinformation and conflicting claims.* **By Maxime Marquette, columnist** ## Columnist's transparency note ### Editorial stance I am not a journalist but a **columnist and analyst**. My expertise lies in observing and analysing the geopolitical, economic and strategic dynamics that shape our world. My work is to take political strategies apart, to understand global economic movements, to put the decisions of international actors in context and to offer analytical perspectives on the changes that are redefining our societies. I do not claim the cold objectivity of traditional journalism, which stops at reporting facts. **I claim analytical clarity**, rigorous interpretation and a deep understanding of the complex issues that concern us all. My role is to give meaning to the facts, to place them in their historical and strategic context, and to offer a critical reading of events. ### Method and sources This text keeps the basic distinction between **verified facts and interpretive analysis**. The rule never changes: a factual claim is published only when a verifiable source supports it, and the sources this article actually used are listed under **Sources**, never here. **Primary source families** used by the publication, when the story has them: official statements from governments and international institutions, public statements by political leaders, reports from intergovernmental organisations, dispatches from recognised international news agencies. **Secondary source families**: specialised publications, internationally recognised news media, analyses from established research institutions, reports from industry organisations. When an article cites statistical, economic or geopolitical data, it comes from the institutions that produce it (intergovernmental organisations, central banks, national statistics offices), and the exact institution is named under **Sources**. ### Nature of the analysis The analyses, interpretations and perspectives in the analytical sections of this article are a **critical, contextual synthesis** based on the information available, the trends observed and the expert comments cited in the sources consulted. My role is to interpret these facts, to set them in the context of today's geopolitical and economic dynamics, and to give them a coherent meaning within the larger story of the changes shaping our time. These analyses reflect expertise built through continuous observation of international affairs and an understanding of the strategic mechanisms that drive global actors. This article describes a documented state of affairs on its publication date, not a prediction: later developments may shift its outlook. No update is promised in advance; when an article is corrected or completed, the change is dated in the text. ## Sources ### Primary sources - [Euronews — Billions of mRNA vaccine doses review underpins their effectiveness — July 1, 2026](https://www.euronews.com/2026/07/01/billions-of-mrna-vaccine-doses-review-underpins-their-effectiveness) - [UBC News — mRNA vaccines are safe, effective and full of promise — June 2026](https://news.ubc.ca/2026/06/mrna-vaccines-are-safe-effective-and-full-of-promise/) ### Secondary sources - [Reason — New study of billions of mRNA vaccine shots confirms their safety and efficacy — July 1, 2026](https://reason.com/2026/07/01/new-study-of-billions-of-mrna-vaccine-shots-confirms-their-safety-and-efficacy/) - [CBC News — mRNA vaccines Lancet review — July 1, 2026](https://www.cbc.ca/news/health/mrna-vaccines-lancet-review-9.7254665) - [Euronews Arabic — Billions of mRNA vaccine doses reviewed confirm their effectiveness — July 1, 2026](https://arabic.euronews.com/health/2026/07/01/billions-of-mrna-vaccine-doses-reviewed-confirm-their-effectiveness) - [The Lancet — official journal page — July 2026](https://www.thelancet.com) --- Source: Maxime Marquette, MadMax. When citing, name the author and link https://mad-max.co/en/article/milliards-de-doses-darnm-que-dit-vraiment-la-science-en-2026